Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Life Expectancy”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 667 records · Page 37Linked to original sources
PubMed1993

Mortality and life expectancy in Poland 10 years before the end of the century.

"In the article we discuss the mortality rates in Poland by [voivodship] at the end of the 80's. In the comparative analysis, we employed general standardized rates of deaths for men and women, and coefficients presenting the levels of mortality resulting from...circulatory system diseases and malignant neoplasms.... In the second part of the paper, we examine the differences in...life expectancy by sex and administrative provinces."

Cause of Death↗
PubMed1993

[Life expectancy of the drug addict].

The exact characterization of the epidemiology of drug-related mortality demands investigations of cross-sectional dates and the pursuit of trends under scientifically correct conditions. At the moment the possibilities of research in this field are limited. This is the reason why conclusions concerning the life expectancy of drug-addicts should be drawn with caution. Although systemic studies are not available and--for different reasons--cannot be expected in the FRG few sample surveys do exist which may be considered indicative of certain trends in mortality. Besides the Netherlands the FRG has become the most important market characterized by a rapid increase in illegal drug traffic. The number of drug-related deaths dramatically rises and the elder age-groups are increasingly concerned with the age-group from 20 top 30 years displaying a significantly increased mortality in connection with drug abuse. The epidemiologic development described so far is supposed even to be aggravated because the i.v.-drug-addicts are at high risk to acquire a hepatitis or HIV-infection.

Adolescent↗
PubMedDate not supplied

Average life expectancy of heterozygous beta thalassemic subjects.

In order to define the lifespan of heterozygous beta thalassemic subjects as compared to non thalassemic subjects, the authors prospectively studied all patients deceased during a period of 76 months at St. Camillo Hospital of Comacchio (Ferrara), located in the Po delta, a region with high prevalence of thalassemia minor. No statistically significant differences were found in the average life expectancy between the thalassemic and non thalassemic groups.

Heterozygote↗
PubMed1993

Effects of long-term elevated serum levels of growth hormone on life expectancy of mice: lessons from transgenic animal models.

In this study, we characterize transgenic mice carrying fusion genes, in which the genes coding for human (h) or bovine (b) growth hormone (GH) have been put under the transcriptional control of the mouse metallothionein I (MT) or the rat phosphoenolpyruvate carboxykinase (PCK) promoter as models for investigating the long-term effects of elevated GH on life expectancy. Circulating GH concentrations ranged from 3000 to 900,000 ng/ml, from 320 to 2960 ng/ml and from 34 to 1050 ng/ml in transgenic mice belonging to the MThGH, the PCKbGH and the MTbGH groups, respectively, and were high on a short-, medium-, and long-term basis. As a consequence of excess GH in their serum, GH transgenic mice exhibited drastically reduced life span which was primarily due to severe kidney lesions (glomerular hypertrophy, sclerosis and hyalinosis associated with tubulo-interstitial changes) consistently found in these animals. Alterations of the liver observed in transgenic mice included both hepatocellular megaly and various degrees of regressive, regenerative and fibrotic changes. In older MTbGH and PCKbGH transgenic mice, hepatocellular neoplasms including both adenoma and carcinoma were frequently found in addition to non-neoplastic changes. Our study points out the suitability of GH transgenic mice to evaluate the effects of various levels of GH in long-term studies without having to take antibody production against the heterologous hormone into account. Findings in GH transgenic animals suggest that the long-term benefits and risks of GH therapy should be carefully evaluated.

Aging↗
PubMed2005

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

PURPOSE: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and life expectancy in these groups as a basis for clinical decision making. PATIENTS AND METHODS: Four hundred sixty-seven patients who were diagnosed as having de novo MDS at the Division of Hematology, University of Pavia (Pavia, Italy), between 1992 and 2002, were evaluated retrospectively for clinical and hematologic features at diagnosis, overall survival (OS), and progression to leukemia (leukemia-free survival). RESULTS: Significant differences in survival were noted between patients with refractory anemia (RA), refractory cytopenia with multilineage dysplasia, RA with excess blasts, type 1 (RAEB-1), and RAEB-2. The effect of demographic factors on OS was observed in MDS patients without excess blasts (age, P = .001; sex, P = .006), as in the general population. The mortality of RA patients 70 years or older did not differ significantly from that of the general population (SMR, 1.62; P = .06). Cytogenetics was the only International Prognostic Scoring System variable showing a prognostic value in MDS classified into WHO subgroups. Transfusion-dependent patients had a significantly shorter survival than patients who did not require transfusions (P < .001). Developing a secondary iron overload significantly affected the survival of transfusion-dependent patients (P = .003). CONCLUSION: These data show that the WHO classification of MDSs has a relevant prognostic value. This classification, along with cytogenetics, might be useful in decisions regarding transplantation. MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable.

Adult↗